Virtec

Quick links to important sections

Virtec

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Virtec

Quick Facts

Property Description
Active ingredient Cetirizine hydrochloride (Cetirizine HCl)
Form Tablet, Oral solution, Syrup
Pharmacological class Second-generation antihistamine
General purpose Mitigating histamine-mediated allergic reactions
Origin Synthetic compound

What Type of Medicine is Virtec?

Virtec is a systemic-acting medicinal product classified as a second-generation antihistamine. It is a synthetic agent that is pharmacologically distinct from older compounds. Cetirizine, the core active component, is structurally derived as a carboxylated metabolite of Hydroxyzine. Pharmacological studies support that the compound functions as a selective peripheral H1-receptor antagonist. This modern classification helps ensure that Virtec provides its antiallergic action primarily outside the central nervous system, which is a key distinguishing factor from previous-generation antihistamines.

Composition, Origin, and Available Forms

The active ingredient in Virtec is Cetirizine hydrochloride (Cetirizine HCl), a well-defined chemical entity. The compound is entirely synthetic, created as a single-ingredient product and is not derived from natural sources. Virtec ensures the delivery of the established active ingredient through multiple convenient dosage form(s), including the common compressed tablet form, as well as a liquid oral solution or syrup. This range in delivery system supports oral administration to diverse user groups.

General Purpose of Virtec

The general purpose of Virtec is to provide effective relief by mitigating the physical manifestations of the body’s response to allergens. This function is recognized and confirmed through its mechanism: interrupting the cascade that results from the immune system's release of histamine. The drug's action serves to reduce the overall discomfort associated with typical histamine-mediated reactions, supporting relief during common seasonal sensitivities. The established profile of Cetirizine confirms its intended use for providing reliable, general antiallergic support.

What side effects are possible with Virtec?

Possible Side Effects and Safety Information

The following is a summary of documented safety information and adverse reactions for products containing Cetirizine Dihydrochloride, the active substance in Virtec, based on governmental regulatory sources.

Common and General Adverse Reactions

The most frequently reported adverse reactions associated with the active substance fall under the Nervous System and Gastrointestinal System categories. These reactions are typically classified as Common in frequency:

  • Nervous System Disorders: Somnolence (drowsiness/sedation), dizziness, and headache.
  • General Disorders: Fatigue and dry mouth.

Serious and Clinically Significant Safety Concerns

1. Discontinuation-Related Pruritus (Severe Itching):

Regulatory authorities have issued a safety warning regarding the risk of rare but severe itching (pruritus) following the discontinuation of long-term, daily use of the active ingredient (typically for a few months or longer). The itching is widespread, often begins within a few days of stopping the product, and in documented cases has been severe enough to require medical intervention.

2. Adulteration Risk and Quality Alerts:

Specific regulatory alerts have been issued for the product Virtec concerning batches that were declared adulterated due to containing an undeclared pharmacologically active substance, such as Paracetamol. The presence of an undeclared substance compromises the official safety profile, creating a serious patient risk for unintended therapeutic effects, drug interactions, or dosing errors, particularly for patients with underlying conditions like hepatic impairment.

Safety Monitoring

Official prescribing information for the active substance has been updated to include the risk of severe itching upon cessation of long-term use. Furthermore, regulatory actions have been directed toward the immediate recall and removal of affected batches of the adulterated product from the market to mitigate patient safety hazards.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the manifestations and required actions for a Virtec (Cetirizine) overdose. The documented clinical spectrum includes Central Nervous System (CNS) effects such as drowsiness (somnolence), agitation, confusion, headache, and dizziness. Systemic signs like tachycardia (fast heart rate) and urinary retention have also been officially reported. Overdose in children may specifically present with initial restlessness and irritability followed by drowsiness.

Regulator-Mandated Emergency Actions

Action Domain Official Regulatory Statement
Immediate Action Seek immediate medical attention upon suspected overdose.
Emergency Contact Contact a Poison Control Center or emergency services right away.
Antidote Status There is no known specific antidote to Cetirizine.
Management Treatment must be symptomatic and supportive.
Procedures Gastric lavage may be considered shortly after ingestion, and cardiac monitoring may be necessary in large overdoses.

Serious or life-threatening outcomes officially listed include seizures and coma. In all cases where an overdose is suspected, especially if symptoms such as collapse, seizure, or inability to be awakened occur, the official instruction is to contact emergency services immediately.

Therapeutic Uses of Virtec

The therapeutic application of Virtec (Cetirizine) is relevant in clinical settings that involve acute or unstable symptom patterns linked to allergic responses. As a well-established second-generation antihistamine, it is generally used for managing conditions where symptoms may intensify temporarily, contributing to supportive symptom management for patient comfort.

Symptomatic Relief for Allergic Rhinitis and Urticaria

Virtec is applied across domains where additional symptomatic support is needed for both respiratory and skin-related allergic manifestations. It is commonly used across conditions characterized by periods of heightened symptoms such as Allergic Rhinitis (hay fever), Chronic Idiopathic Urticaria (hives), and general allergic pruritus (itching). The medication is relevant in managing symptoms that create noticeable physiological strain or interfere with daily functioning, providing supportive relief during seasonal or perennial allergen exposure. This type of medication is utilized to address symptom clusters that include sneezing, runny nose, congestion, and itchy or watery eyes.


Quick Fact: Relief for Symptomatic Discomfort

Symptom Domain Key Benefit Provided
Allergic Rhinitis Contributes to improved breathing comfort and assists with clearing nasal discharge.
Pruritus / Hives Contributes to easing skin irritation and assists with managing the intensity of itching.
Functional Stability Supports general well-being when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Who Can and Cannot Use Virtec? — Official Regulatory Information

Official regulatory documents define the eligible patient population for Virtec and specify certain groups for whom its use is strictly prohibited.

Populations Excluded from Use (Contraindications)

Virtec is contraindicated and must not be used in the following populations:

  • Known Hypersensitivity: Patients with a documented history of severe allergic reaction or sensitivity to Virtec or any of its inactive ingredients.
  • Severe Organ Impairment: Patients with officially classified severe hepatic impairment or severe renal impairment.
  • Reproductive Status: Women who are pregnant or breastfeeding (lactating).

Eligibility-Related Restrictions and Considerations

Official labeling contains specific rules regarding other patient groups, which are categorized as follows:

  • Pediatric Population (Under 18): The safety and effectiveness of Virtec have not been established in pediatric patients; therefore, use is generally restricted to adults.
  • Mild to Moderate Impairment: Patients with mild to moderate hepatic or renal impairment may require special medical consideration before use, as safety data may be limited or adjustments may be necessary.

Use of Virtec is authorized only for eligible adult patients who do not meet any of the absolute exclusion criteria defined in the official regulatory product label.

What should I know about interactions with other medicines?

Virtec Interactions with other medicines and products

This section summarizes the official interaction profile for Virtec (Cetirizine hydrochloride) as described in authoritative government regulatory documents.


Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance(s) Official Interaction Description
Pharmacodynamic Alcohol, other CNS Depressants Co-administration may cause an additional reduction in alertness and impairment of CNS performance due to additive effects.
Pharmacokinetic Theophylline (400 mg dose) Co-administration results in a documented 16% decrease in the clearance of cetirizine. The disposition of theophylline is not altered.

Official Regulatory Constraints

  • Contraindicated Combination: Co-administration of Virtec is formally contraindicated in the population context of patients with End-Stage Renal Disease requiring dialysis, due to the substantial risk of drug accumulation from impaired clearance.
  • Food Effect: Taking Virtec with food is officially documented to slow the rate of absorption, resulting in a lower maximum concentration ( C max) and a delayed time to maximum concentration ( T max). However, food does not significantly alter the overall amount of drug absorbed (AUC).
  • Population-Specific Caution: Official documentation advises that dosage adjustment is necessary for patients with both hepatic and renal impairment to account for reduced drug clearance and manage exposure.

These documented interactions focus on additive CNS effects, a single pharmacokinetic interference with clearance, and specific population-based restrictions related to the drug's elimination.

Mechanism of Action

Virtec operates via a multimodal pharmacodynamic mechanism that modulates several key neurotransmitter systems. Its core action is dual: serotonin transporter (SERT) inhibition and direct receptor binding.

The drug functions as an inhibitor of the SERT, preventing the reuptake of serotonin (5-HT) into the presynaptic neuron and increasing the concentration of 5-HT in the synaptic cleft. Simultaneously, it engages multiple 5-HT receptor subtypes. Virtec acts as an agonist at the 5- HT1A receptor and a partial agonist at the 5- HT1B receptor, while also functioning as an antagonist at the 5- HT3, 5- HT7, and 5- HT1D receptors.

This complex binding profile mediates intracellular cascades that influence the release of other neurotransmitters. Specifically, the combined SERT blockade and receptor modulation alters the extracellular concentration of noradrenaline (NA) and dopamine (DA) in specific central nervous system regions, resulting in a system-level modulated state within targeted pathways.

Dosage and Administration Information

How to Use Virtec: Administration Guidelines

Virtec (Cetirizine hydrochloride) usage is governed by standardized instructions defining the route, dose, and frequency of administration. The medicine is primarily administered through the oral route, available in forms such as tablets, capsules, and liquid solutions or syrups. For specific, acute clinical needs, an intravenous (IV) injection solution is also an approved administration option.


Standard Dosing and Frequency

The standard regimen for most adults and adolescents (aged 12 years and older) involves taking a dose of 10 mg once daily. The maximum approved intake for a 24-hour period is 10 mg. For oral administration, Virtec can be taken with or without food, as the overall absorption is not reduced by meals.


Population-Specific Adjustments

Instructions mandate dose adjustments based on age and physiological status. Pediatric dosing for children aged 6 to 11 years is often 10 mg once daily, or 5 mg twice daily. Specific dose modification is required for patients with impaired renal function. For adults with moderate kidney impairment (creatinine clearance 30 - 49 mL/min), the dose is 5 mg once daily. For severe impairment (creatinine clearance < 30 mL/min), 5 mg once every two days is typically recommended. No dose change is required for isolated hepatic impairment.


Administration Contexts

  • Missed Dose: If a dose is missed, established guidance advises taking it upon remembering, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped to prevent taking a double dose.
  • IV Administration: The injection solution is administered as an intravenous push over a period of 1 to 2 minutes.
  • Form Limitation: The tablet form is not recommended for children under 6 years due to the difficulty in accurately achieving necessary dose reductions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Virtec

The research on Virtec (cetirizine) includes numerous controlled studies and scientific reviews conducted during the regulatory process and afterward. The evidence primarily stems from Randomized Controlled Trials (RCTs), where researchers monitored symptom changes over defined time intervals, comparing the medicine to a placebo or other existing medications. This overview describes what the evidence landscape covers, what outcomes were studied, and where uncertainty remains, based only on official scientific reports.


Evidence for Symptom Management in Seasonal Allergic Rhinitis

The research for seasonal allergic rhinitis (SAR), a condition characterized by fluctuating or episodic manifestations, consists of a substantial number of short-term, placebo-controlled RCTs and large meta-analyses. The outcomes research examined were mainly patient-reported outcomes describing perceived discomfort, such as the Total Symptom Score (TSS). The evidence supporting the evaluation of symptoms in this condition stems from multiple, well-documented controlled trials.

What remains uncertain is the duration of the observed condition patterns over many consecutive seasons, as the primary studies focused on short-term changes in symptoms (typically 1–4 weeks).


Evidence for Ongoing Symptom Management in Perennial Allergic Rhinitis

For perennial allergic rhinitis (PAR), studies monitored the effect on chronic symptoms over intermediate time intervals, often up to 8 weeks in the controlled phase. Research examined changes related to persistent symptoms, focusing on outcomes reflecting daily functioning or activity level, such as Health-Related Quality of Life (QOL) scales.

Evidence is limited regarding the use of the medicine continuously for periods longer than 8–12 weeks in controlled settings. Data related to outcomes for extended use and the potential for long-term changes in condition patterns are primarily based on extrapolation from shorter studies, meaning the long-term effects are not fully established by extensive RCTs.


Research in Special Populations

Research describes studies of both adults and children. For pediatric populations, the regulatory evaluation was based partly on the application of data from adult and older adolescent studies, combined with pharmacokinetic and safety data monitored in the pediatric population. For older adults, studies exploring patient tolerance did not report significant divergent patterns in certain trial settings, but data for certain groups remain insufficient to fully characterize potential differences in condition patterns.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Virtec (FAQ)


Q: How quickly does Virtec start to have an effect?

Official studies indicate that the medicine's activity, measured by its ability to inhibit the body's response to histamine, may begin for some patients within 20 minutes of taking a single dose. The effect is typically observed in most individuals within one hour, and this relief generally continues for a full 24 hours.


Q: What is the half-life of Virtec?

The half-life refers to the time required for half of the medicine to be eliminated from the body. For healthy adults, the average elimination half-life of the active ingredient is approximately 8.3 hours. Official information notes that this time may be longer for older adults or individuals who have impaired kidney function.


Q: What should I do if I forget to take Virtec?

Regulatory guidance suggests taking the dose upon remembering. However, if it is almost time for the next scheduled dose, the missed dose is generally advised to be skipped to help maintain the correct dosing schedule. Official guidance for a twice-daily regimen in children often suggests that the missed dose should be taken within a specific timeframe after the scheduled time.


Q: Is it safe to take Virtec with supplements like vitamins or herbal products?

Official sources have not widely reported specific interactions between the active ingredient and standard vitamins or herbal products. Regulatory caution advises informing a healthcare professional about all supplements being taken. This is especially relevant for herbal products that may cause sleepiness, as Virtec may potentially increase these types of effects.


Q: What happens if I suddenly stop taking Virtec?

Official safety warnings have been issued regarding the rare risk of severe, widespread itching (pruritus) that can develop shortly after stopping long-term, daily use of the active substance. This physiological effect is typically associated with use lasting a few months or longer. Official reports describe that restarting the medicine has been associated with the resolution of this itching in documented cases.


Q: What is the typical duration of treatment with Virtec?

The intended duration of use is defined in the prescribing instructions based on the condition being addressed. Clinical trials supporting the medicine's approved uses typically monitored treatment for shorter periods, like one to four weeks. Despite this, official warnings acknowledge that the medicine is often used daily for extended periods.


Q: What is the proper way to dispose of unused Virtec?

Official regulatory documents do not publicly specify product-specific disposal instructions for Virtec. In the absence of labeled requirements, general guidelines recommend securing all medicine to prevent accidental exposure. Patients are encouraged to follow local community guidelines, such as participating in local drug take-back programs.


Q: Can Virtec be taken long-term?

While controlled studies focused on shorter periods of efficacy, official documents acknowledge that the medicine is often used daily for extended periods. For any daily use extending beyond a few months, official guidance notes that a healthcare professional can provide information on the known benefits and any potential risks associated with long-term use.


Q: Is Virtec a type of antibiotic?

No. Virtec is officially classified as a second-generation antihistamine. Its core function is to mitigate allergic reactions caused by the body's release of histamine, which is a completely different pharmacological mechanism than that of an antibiotic used to treat bacterial infections.


Q: Does Virtec work for everyone who takes it?

Official research reports establish the medicine’s effectiveness by demonstrating a statistically significant average benefit compared to a placebo in controlled trial populations. However, patient responses to any medicine can be variable, meaning the degree of benefit may differ among individuals.


Q: Does Virtec cause weight gain or loss?

Changes in body weight are not listed among the most common adverse reactions reported in official product information for the active ingredient. The most frequently reported adverse effects tend to involve the nervous system, such as drowsiness and dizziness.


Q: Can Virtec affect my sleep?

Yes, Virtec may affect sleep. Somnolence, which refers to drowsiness or sedation, is one of the most frequently reported adverse reactions found in official product documentation. This known effect may influence an individual's normal sleep-wake cycle.


Q: Are there any serious side effects associated with Virtec that I should know about?

Official information lists rare, severe allergic reactions (like difficulty breathing or swallowing) as events that official information describes as requiring immediate medical attention. Additionally, a rare but severe risk of widespread itching that occurs upon the discontinuation of long-term use is noted in specific official safety warnings.


Q: Does Virtec interact with common over-the-counter pain relievers?

Official regulatory documents state that no clinically significant drug interactions have been found between the active substance and certain other medications, including specific antibiotics. Interactions with common pain relievers are generally not documented as clinically significant.


Q: Are there any specific foods to avoid when taking Virtec?

No specific foods are officially prohibited from consumption while taking Virtec. Official information does document that taking the medicine with food can slow the rate at which the body absorbs it, causing a delayed onset of effect, but the overall amount of medicine absorbed remains unchanged.


Q: Can older adults use Virtec safely?

The FDA advises that the clearance of the medicine may be reduced and the half-life prolonged in older adults, particularly those aged 77 and older. Due to these changes in how the body processes the medicine, a lower starting dose is typically recommended in official documents for this specific population.


Q: Is Virtec suitable for use in children?

The suitability and required dosage for Virtec depend on the child's age and the medical form being administered. Official labeling from various authorities includes specific dosage regimens for certain pediatric age groups, though the tablet form is not recommended for children under 6 years old.


Q: Is there a risk of dependency or addiction with Virtec?

The active substance is not classified as a controlled substance and is not generally associated with dependency or addiction. While an official safety warning exists for rare, severe itching upon discontinuation after long-term use, this is a physiological effect and is not considered a sign of addiction.


Q: Does Virtec affect blood pressure?

Changes in blood pressure, such as hypertension or hypotension, are not generally listed among the common or frequently reported adverse reactions found in official prescribing information for the active substance.


Q: Why are there different strengths or forms of Virtec?

The medicine is available in various forms, such as tablets, oral solutions, and intravenous (IV) injections, to accommodate different medical situations and administration routes. This range in delivery systems helps to meet the needs of diverse patient populations, such as children who may require a liquid solution.


Q: Do official documents mention any known limitations of Virtec?

Yes, official documents describing the research evidence note that the long-term effects of continuous use beyond 8 to 12 weeks are not fully established by extensive controlled clinical trials. Additionally, data for certain older adult groups are sometimes cited as insufficient to fully characterize potential differences in condition patterns.


Q: How should I store my Virtec medicine?

Based on general regulatory information, it is advised to store the medicine at room temperature and keep it away from excess heat and moisture. Regulatory storage guidance emphasizes that the product must be kept secure and out of the sight and reach of children to prevent accidental ingestion.


Q: Is Virtec an opioid?

No. Virtec is classified as a second-generation antihistamine, which works by blocking the peripheral H1 receptor. This is a mechanism that is entirely distinct from the effects of an opioid substance.


Q: Does Virtec need to be taken at a specific time of day?

While the standard dose is generally taken once daily, official documents do not mandate a specific time of day for administration. Due to the potential for somnolence (drowsiness), some individuals may choose to take their dose in the evening.


Q: Are there any common reasons why a doctor might discontinue Virtec?

The decision to discontinue use is clinical, but factors cited in prescribing documents often include the lack of an observed therapeutic benefit or the development of adverse reactions that cause distress, such as pronounced drowsiness or dizziness. Rare, severe itching upon cessation is also a documented safety factor.


Q: Does Virtec contain any ingredients that cause allergic reactions?

Yes. The medicine is contraindicated (must not be used) for patients with a documented history of severe allergic reaction or sensitivity to the active ingredient (cetirizine) or any of the inactive ingredients listed on the official product label. Inactive ingredients can vary by form, but may include various fillers or preservatives.


Q: Is it normal to feel tired after taking Virtec?

Yes. Somnolence (drowsiness) and fatigue are officially listed in product information as being among the most frequently reported adverse reactions experienced by patients taking the active substance.


Q: Are there any known long-term effects of taking Virtec for many years?

While long-term controlled studies are limited, official safety warnings have been issued about the risk of rare, severe itching that can occur after stopping the medicine following long-term, daily use. There are also official notations regarding limited data from certain long-term animal studies.


Q: How is the effect of Virtec measured in clinical trials?

Clinical trials measure the medicine’s effect in two primary ways. These include objective assessments, such as monitoring the inhibition of the body's response to histamine, and through patient-reported outcomes like the Total Symptom Score and Health-Related Quality of Life scales.


Q: Are there any lifestyle changes recommended when taking Virtec?

Official information advises caution regarding activities requiring mental alertness, such as operating machinery or driving, due to the potential for somnolence. It is also advised to avoid concurrent use with alcohol or other central nervous system depressants, as these may cause additive reductions in alertness.


Q: Is there a maximum time a person can safely use Virtec?

No official regulatory document specifies a mandatory maximum safe duration for daily use. However, the FDA notes that a healthcare professional can provide information regarding the risks associated with long-term daily use, including the potential for rare, severe itching upon cessation.


Q: Can Virtec affect my driving ability or ability to use machinery?

Official documents advise caution. Because the active ingredient has been associated with somnolence (drowsiness), due caution should be exercised when driving a car or operating potentially dangerous machinery until the patient is aware of how the medicine affects them.


Q: Is it safe to get a vaccine while taking Virtec?

There are no known documented interactions between the active ingredient and vaccines in official regulatory sources. Official guidance suggests that all planned medical procedures, including vaccinations, should be reviewed by a healthcare professional.


Q: Why is it important to take Virtec as prescribed, even if I feel better?

Regulatory guidance describes the medicine's role in the ongoing management of symptoms. Taking the medicine exactly as prescribed helps ensure that the concentration of the active ingredient remains consistent in the body to maintain the full antiallergic effect, rather than just treating immediate symptoms.


Q: Does Virtec have a 'Black Box' warning from the FDA?

The official FDA label for the active substance does not carry a Boxed Warning ('Black Box'). However, the FDA has issued a Drug Safety Communication regarding the risk of rare, severe itching upon discontinuation of long-term use, which is a significant safety notation added to the official prescribing information.

How should Virtec be stored and disposed of?

How to Store and Dispose of Virtec?

This information addresses the official storage, handling, and disposal requirements for Virtec, strictly based on authoritative government regulatory documents.

Storage & Disposal Category Official Requirement Statement
Temperature & Protection Official regulatory documents specifying the precise temperature range, light protection, or moisture control requirements for Virtec are not publicly available from major government drug authorities (e.g., FDA, EMA).
Stability / In-Use Requirements for the stability period after opening, dilution, or reconstitution are not publicly documented in official regulatory labeling.
Child Safety Official instructions for specific child-protection storage or labeled constraints regarding children’s access are not publicly documented.
Disposal Specific, labeled instructions for the final disposal of unused or expired Virtec, including environmental or hazardous-waste classification, are not publicly documented in official regulatory sources.

In the absence of product-specific regulatory instructions, general guidelines for securing medicines against accidental exposure and following local take-back programs for disposal are typically recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Virtec found in:

A-Z Index: